Loading
Life sciences · Journal article
Anticancer Research · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Aim: Cancer-associated hypercalcemia is commonly a paraneoplastic manifestation of ectopic parathyroid hormone-related protein (PTHrP) production. Although serum calcium is routinely monitored, it can be influenced by antiresorptive therapy, albumin concentration, vitamin D status, and other clinical factors. Because durable control of hypercalcemia depends on effective anticancer therapy, serial PTHrP measurement may provide a more direct marker of treatment efficacy than serum calcium alone. Case Report: A 66-year-old woman with extensive cutaneous squamous cell carcinoma (CSCC) of the scalp was considered unsuitable for primary surgical extirpation and was treated with the immune checkpoint inhibitor cemiplimab. While awaiting insurance approval, she was hospitalized with severe hypercalcemia. After one course of cemiplimab, both serum calcium and PTHrP were mildly elevated. After the second course, serum calcium fell to the low-normal range, whereas PTHrP rose markedly. Subsequent imaging showed rapid progression with metastases to the bone, brain, lung, and liver, and the patient died shortly thereafter. Conclusion: In progressive malignancy, PTHrP detected by immunoassay may increase even when serum calcium normalizes or declines. This case suggests that serial PTHrP levels may be more informative than serum calcium alone for assessing anticancer treatment efficacy in PTHrP-mediated hypercalcemia.